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Abstract
BACKGROUND: Abnormalities of glucose metabolism in diabetes can be an independent risk factor for the 
development and prognosis of cancer; it caused endothelial cell activation, inflammatory reactions. Hemostatic 
disorders, thrombosis, and various human organ damaged that will increase the morbidity and mortality rate. 
Diabetes was predicted to reach 552 million by 2030 in conjunction with rapid social and cultural changes. With the 
changes in lifestyle, body mass index (BMI) plays an important role in increasing the risk of metabolic diseases like 
diabetes type 2. One sign of endothelial cell activation is an increase in Von Willebrand Factor, which can be an early 
sign of increased coagulation activation until thrombosis occurs.
AIM: The aim of the study was to determine the correlation between BMI, glucose control, and endothelial cell 
activation in malignancy with diabetes patients.
METHODS: This is a case-control study with eighty samples. BMI, HbA1C, vWF, and D’dimer were measured.
RESULTS: There is a statistical significant correlation between blood glucose and HbA1C (p = 0.00), blood glucose 
and BMI (p = 0.037), HbA1C an BMI (p = 0.029), HbA1C and vWF (p = 0.03), HbA1C and age (p = 0.009), D’Dimer 
and vWF (p = 0.00), and age and BMI (p = −0.019), but no statistical significant between vWF and BMI (p = 0.97), 
vWF and age (p = 0.36).
CONCLUSIONS: There was an increased risk of thrombosis in malignancy with diabetes cases. BMI showed a 
significant correlation with blood glucose controlled, blood glucose control showed a significant correlation with the 
activation of the endothelial cell and hypercoagulable state.
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Introduction
Diabetes mellitus (DM) and malignancy are two 
chronic diseases which have a major impact on health 
population, both contribute to the increase of morbidity 
and mortality worldwide. DM is a chronic metabolic 
disease presented with chronic hyperglycemia due to 
insufficiency or resistance of insulin. The prolonged 
hyperglycemia will impair and damaged various 
human organ systems [1], [2]. Abnormalities of glucose 
metabolism in diabetes can be an independent 
risk factor for the development and prognosis of 
cancer [3], [4]. Hyperinsulinemia, insulin resistance, 
obesity, medications, and diet may play an important 
role. Several studies have shown the increased 
incidence of several cancers such as pancreas, colon, 
kidney, breast, stomach, liver, and endometrium in 
diabetes [5] and it has been reported that chronic 
hyperglycemia can promote tumor cell proliferation and 
metastasis in type 2 diabetes [6].
The prevalence of diabetes is globally 
increasing and is considered as an endemic chronic 
disease [7]. Diabetes, in conjunction with rapid social 
and cultural changes, aging population, urbanization, 
lifestyle [8], has affected more than 366 million, and 
it was predicted to reach 552 million by 2030 [7]. 
Increased in body mass index (BMI) is associated with 
an increased risk of metabolic diseases like diabetes 
type 2 [9].
Chronic hyperglycemia in diabetes can cause 
endothelial cell activation, inflammatory reactions. 
Hemostatic disorders, thrombosis, and various human 
organ damaged that will increase the morbidity and 
mortality rate [10]. One of the markers of endothelial 
cell activation is Von Willebrand Factor, a multimeric 
glycoprotein synthesized by megakaryocytes and 
endothelial cells [11]. Increased levels of vWF 
levels indicate hypercoagulable state [12] and 
are associated with the progression of micro and 
macrovascular dysfunction [13], [14]. Cancer was 
known as a prothrombotic disease [15], and most of 
the cause of death in cancer was thrombosis [16]. 
Abnormal vascularization of the tumor will result 
in endothelial cell activation. Changes in tumor 
biology, activation of coagulation, and inflammation 
all explain the pathogenesis of thrombosis in cancer 
patients [17], [18].
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Aim
This study was to evaluate the relation between 
stages of BMI, glucose control, and endothelial cell 
activation in malignancy with diabetic patients.
Methods
This is a case-control group with eighty 
samples, collected from Murni Teguh Memorial Hospital 
Medan Indonesia. All malignancy cases are solid tumor 
and were diagnosed with pathology reports. Diabetes 
was determined by the random blood glucose level 
above 140 mg/dl and HbA1C above or equal to 6.5.
Laboratory measurements
Blood glucose was measured using 
spectrophotometry, HbA1C using HPLC assay, HbA1C 
was used to determine the blood glucose controlled 
level. vWF was measured to determine the endothelial 
cell activation using enzyme-linked immunosorbent 
assay (ELISA). D’dimer was used to determine the 
hypercoagulable state, this was measured using the 
ELISA method. The measurement was done after 
fasting at least 9 h. BMI was determined by calculating 
body weight and height according to the standardized 
protocols [19]. Data were analyzed using SPSS 22.
Ethics, consent, and permissions
This study has been approved by the Medical 
Ethical Committee of Medical Faculty Universitas 
Sumatera Utara Medan Indonesia. All participants were 
provided with written informed consent before the study.
Results
Eighty samples of malignancy with diabetes 
were recruited. They were 38.8% male and 61.3% 
female with the ages rank from 30 to 73 years old. The 
mean age is 54 years old. The mean HbA1C was 6.3, 
there were 77.5% samples with well-controlled blood 
glucose level and 22.5% samples with a bad controlled 
glucose level. The mean BMI was 24, the distribution of 
BMI with normal weight was 71.3%, overweight 21.3%, 
and obese 7.5%. The mean vWF was 53, with 30% of 
samples develop endothelial cell activation, and the 
mean D’dimer was 1.1, with 67.5% samples were in 
hypercoagulable state (Table 1).
Spearman’s rho correlation was used to 
determine the correlation between variables, there is a 
statistical significant between blood glucose and HbA1C 
(p = 0.00), blood glucose and BMI (p = 0.037), HbA1C and 
BMI (p = 0.029), HbA1C and vWF (p = 0.03), HbA1C 
and age (p = 0.009), D’dimer and vWF (p = 0.00), and age 
and BMI (p = −0.019), but no statistical significant between 
vWF and BMI (p = 0.97), vWF and age (p = 0.36).
Discussion
In this study, most of the blood glucose levels 
were well controlled. BMI has a significant correlation 
with age and blood glucose control, this also has been 
proved by Satwanti et al. [20], they stated that BMI was 
found to be associated with age independently. Blood 
glucose has a positive correlation with BMI has been 
reported by Neelam et al. [21]. There was activation 
of the endothelial cell at thirty percent of the samples 
(normal limit above 50 IU), and this has been reported 
by Mark et al (2003) and Horowitz and Brenner (2008). 
vWF also reported to increase at several conditions 
such as inflammation and infection disorders. Blood 
glucose control has a significant correlation with 
endothelial cell activation, age, and BMI, as has been 
reported before by other researches, with the activation 
of the endothelial cell will lead to hypercoagulable state; 
in this study, we got 67.5% cases with activation of 
coagulation.
Table 1: Laboratory and descriptive tests of the samples
Variable n Minimum Maximum Mean SD
HbA1C (%) 80 2.40 12.70 6.3 2.07
D’dimer (mcg/ml) 80 0.13 4.50 1.1 0.96
Blood glucose (mg/dl) 80 50 635 183 109.5
BMI 80 17.70 38.71 24 4.09
Body weight (kg) 80 40 85 55 9.6
vWF (iu) 80 1.00 436.60 53 71.7
Age (years) 80 30 73 54 9.4
Conclusions
With all the above findings, there was an 
increased risk of thrombosis in malignancy with diabetes 
cases that can worsen the prognosis of the disease. 
BMI showed a significant correlation with blood glucose 
controlled, blood glucose control showed a significant 
correlation with the activation of the endothelial cell and 
hypercoagulable state.
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